Literature DB >> 32156516

Performance of the Finnish Diabetes Risk Score (FINDRISC) and Modified Asian FINDRISC (ModAsian FINDRISC) for screening of undiagnosed type 2 diabetes mellitus and dysglycaemia in primary care.

Hooi Min Lim1, Yook Chin Chia2, Zhong Lin Koay3.   

Abstract

AIMS: To evaluate the performance of FINDRISC and ModAsian FINDRISC for the screening of undiagnosed diabetes and dysglycaemia in primary care. To compare the performance of FINDRISC with the recommendations of the American Diabetes Association (ADA) and US Preventive Services Task Force (USPSTF) guidelines.
METHODS: This cross-sectional study was carried out on 293 patients without a prior history of diabetes at a primary care clinic in Malaysia. Questions on body mass index and waist circumference were modified based on the Asian standard in ModAsian FINDRISC. Haemoglobin A1c of ≥6.5% (48 mmol/mol) was used to diagnose diabetes. Areas under the receiver operating curve (ROC-AUC) for FINDRISC and ModAsian FINDRISC were analyzed.
RESULTS: The prevalence of undiagnosed diabetes was 7.5% and prediabetes was 32.8%. The ROC-AUC of FINDRISC was 0.76 (undiagnosed diabetes) and 0.79 (dysglycaemia). There was no statistical difference between FINDRISC and ModAsian FINDRISC. The recommended optimal FINDRISC cut-off point for undiagnosed diabetes was ≥11 (Sensitivity 86.4%, Specificity 48.7%). FINDRISC ≥11 point has higher sensitivity compared to USPSTF criteria (72.7%) and higher specificity compared to the ADA (9.6%).
CONCLUSIONS: FINDRISC is a useful diabetes screening tool to identify those at risk of diabetes in primary care in Malaysia.
Copyright © 2020 Primary Care Diabetes Europe. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Diabetes risk score; Diabetes screening; Dysglycaemia; HbA1c; Undiagnosed diabetes

Year:  2020        PMID: 32156516     DOI: 10.1016/j.pcd.2020.02.008

Source DB:  PubMed          Journal:  Prim Care Diabetes        ISSN: 1878-0210            Impact factor:   2.459


  5 in total

Review 1.  Recent Developments in Biomarkers for Diagnosis and Screening of Type 2 Diabetes Mellitus.

Authors:  Margarita Ortiz-Martínez; Mirna González-González; Alexandro J Martagón; Victoria Hlavinka; Richard C Willson; Marco Rito-Palomares
Journal:  Curr Diab Rep       Date:  2022-03-10       Impact factor: 5.430

2.  Translation and performance of the Finnish Diabetes Risk Score for detecting undiagnosed diabetes and dysglycaemia in the Indonesian population.

Authors:  M Rifqi Rokhman; Bustanul Arifin; Zulkarnain Zulkarnain; Satibi Satibi; Dyah Aryani Perwitasari; Cornelis Boersma; Maarten J Postma; Jurjen van der Schans
Journal:  PLoS One       Date:  2022-07-21       Impact factor: 3.752

3.  Development and validation of a new diabetes index for the risk classification of present and new-onset diabetes: multicohort study.

Authors:  Shinje Moon; Ji-Yong Jang; Yumin Kim; Chang-Myung Oh
Journal:  Sci Rep       Date:  2021-08-03       Impact factor: 4.379

4.  Economic evaluation of population-based type 2 diabetes mellitus screening at different healthcare settings in Vietnam.

Authors:  Phung Lam Toi; Olivia Wu; Montarat Thavorncharoensap; Varalak Srinonprasert; Thunyarat Anothaisintawee; Ammarin Thakkinstian; Nguyen Khanh Phuong; Usa Chaikledkaew
Journal:  PLoS One       Date:  2021-12-23       Impact factor: 3.240

5.  Comparison of the Finnish Diabetes Risk Score Model With the Metabolic Syndrome in a Shanghai Population.

Authors:  Shenyi Jin; Qingguang Chen; Xu Han; Yahua Liu; Mengjie Cai; Zheng Yao; Hao Lu
Journal:  Front Endocrinol (Lausanne)       Date:  2022-02-22       Impact factor: 5.555

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.